Question explored with the scientific record
What can you do about bph
The short version: BPH treatment is a real choice, and the evidence shows several options work, but the drug studies are mostly industry-funded and the long-term safety data is thin.
You have a few paths here. The first is lifestyle. Smoking worsens BPH symptoms, and quitting for ten years or more cuts inflammation and storage problems [16]. Metabolic syndrome, especially diabetes and high blood pressure, speeds up BPH progression [17]. So diet and exercise matter more than most doctors will tell you.
The drug options are well-studied but the studies are all funded by the manufacturers. Alpha-blockers like tamsulosin and silodosin relax prostate muscle and improve flow within weeks. The CombAT trial (4,844 men, funded by the maker of dutasteride) found that combining an alpha-blocker with a 5-alpha-reductase inhibitor like dutasteride cut the risk of acute urinary retention by about 68% and surgery by about 71% over four years, compared to the alpha-blocker alone [1, 15]. Tadalafil, the erectile dysfunction drug, also improves BPH symptoms by about 2.4 points on the IPSS scale more than placebo, and helps sexual function at the same time [3]. The catch: these drugs have side effects. Alpha-blockers cause dizziness and low blood pressure when you stand up. The 5-alpha-reductase drugs cause sexual side effects in a meaningful minority of men.
| Treatment | IPSS improvement (points) | Risk reduction vs placebo or monotherapy | Key side effects |
|---|---|---|---|
| Tamsulosin (alpha-blocker) | -6.8 at 12 weeks [21] | - | Dizziness, orthostatic hypotension |
| Silodosin (alpha-blocker) | -8.3 at 12 weeks [21] | - | Retrograde ejaculation (~28%) |
| Dutasteride + tamsulosin (combination) | -6.3 at 4 years [1] | 68% fewer AUR events, 71% fewer surgeries vs tamsulosin alone [1] | Sexual dysfunction, breast tenderness |
| Tadalafil 5 mg daily | -6.0 vs -3.6 placebo [3] | - | Headache, dyspepsia, back pain |
If drugs fail or you want to avoid them, the minimally invasive procedures have better safety data than the older surgeries. Aquablation (water-jet surgery) was tested in a randomized trial against standard TURP: it had a 10% rate of ejaculation problems versus 36% for TURP, and similar symptom improvement [6]. Prostatic artery embolization is another option, with a 2021 study of 160 men showing good symptom relief and no reported serious adverse events [11]. The 2025 review of current options confirms that water vapor therapy and prostatic urethral lift also preserve sexual function better than older surgeries [26].
My call: for mild to moderate symptoms, start with lifestyle changes and smoking cessation. If you need drugs, tadalafil is a reasonable first choice if you also have erectile issues; otherwise an alpha-blocker like silodosin works well. Avoid combination therapy unless your prostate is large and you accept the sexual side effects. For men who want to avoid long-term drugs, Aquablation or prostatic artery embolization have the best safety profiles among the procedures. Confidence: moderate for drug efficacy (the trials are real but industry-funded), moderate for procedural safety (the trials are smaller but more independent).
Sources used 9
-
The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study
The CombAT study demonstrates that combination therapy with dutasteride and tamsulosin significantly reduces the risk of acute urinary retention and BPH-related surgery compared to tamsulosin alone in men with moderate-to-severe lower urinary tract symptoms due to benign prostat…
DOI: 10.1016/j.eururo.2009.09.035 -
Effects of Tadalafil on Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia and on Erectile Dysfunction in Sexually Active Men with Both Conditions: Analyses of Pooled Data from Four Randomized, Placebo-Controlled Tadalafil Clinical Studies
This study evaluates the efficacy and safety of tadalafil 5 mg once daily compared to placebo in treating lower urinary tract symptoms secondary to benign prostatic hyperplasia and erectile dysfunction in sexually active men, demonstrating significant improvements in both condit…
DOI: 10.1111/jsm.12212 -
WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation ® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia
This study compares the safety and efficacy of Aquablation versus transurethral resection of the prostate (TURP) for treating lower urinary tract symptoms due to benign prostatic hyperplasia, finding Aquablation to be noninferior with a lower risk of sexual dysfunction.
DOI: 10.1016/j.juro.2017.12.065 -
Association between intravesical prostatic protrusion and clinical outcomes in prostatic artery embolization
A retrospective, single‑center study of 160 men undergoing prostatic artery embolization for lower urinary tract symptoms due to benign prostatic hyperplasia shows that intravesical prostatic protrusion (IPP) severity influences symptom and quality‑of‑life improvements but does …
DOI: 10.1016/j.diii.2020.12.003 -
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4‐year results from the randomized, double‐blind Combination of Avodart and Tamsulosin (CombAT) trial
The study evaluates the long-term clinical outcomes of combined therapy with dutasteride and tamsulosin versus monotherapy in men with benign prostatic hyperplasia (BPH), demonstrating that combined therapy significantly reduces the risk of acute urinary retention and BPH-relate…
DOI: 10.1111/j.1464-410x.2011.10124.x -
Duration of smoking cessation is negatively associated with the magnitude of chronic prostatic inflammation and storage dysfunction in patients with benign prostatic hyperplasia
A retrospective study of 118 men with benign prostatic hyperplasia shows that longer smoking duration is linked to worse storage dysfunction and higher systemic inflammation, while longer smoking cessation duration is associated with milder storage dysfunction and reduced chroni…
DOI: 10.1111/iju.14320 -
The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome: A Prospective Study
A 3-year prospective cohort study of 525 community-dwelling men with LUTS/BPH found that metabolic syndrome, especially diabetes and hypertension, accelerates clinical progression of BPH, evidenced by greater increases in IPSS and prostate volume and decreased maximum flow rate …
DOI: 10.1159/000448484 -
Silodosin in the treatment of benign prostatic hyperplasia
A critical review of silodosin, a highly selective alpha-1A adrenergic receptor antagonist, for treatment of LUTS/BPH, detailing its mechanism, pharmacokinetics, clinical efficacy versus placebo and other alpha-blockers, safety profile, and long-term outcomes based on Japanese a…
DOI: 10.2147/DDDT.S10428 -
Management and Treatment of Benign Prostatic Hyperplasia Symptoms: Current Insights
A comprehensive, guideline-informed synthesis of BPH-related LUTS pathophysiology, diagnostic evaluation, and the full spectrum of current management options—from lifestyle and medical therapy to minimally invasive therapies and surgical interventions—emphasizing mechanism-based…
DOI: 10.2147/rru.s510367